Novo Nordisk A S (NVO)

Novo Nordisk A/S (NYSE:NVO) was at the center of media coverage as it sued rival weight loss drug manufacturer Eli Lilly on Tuesday.

Dividend stocks have long attracted investors looking for a reliable source of income. They also continue to draw attention from market analysts.

Novo Nordisk A/S (NYSE:NVO) is one of the best low volatility stocks to buy under $50.

On June 18, Tom Lee, Fundstrat's Managing Partner and Head of Research, appeared on CNBC's ‘Closing Bell’ to talk about where stocks are headed from Thursday’s levels.

Separately, on June 11, Novo Nordisk A/S (NYSE:NVO) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) approved the oral version of Wegovy for weight management in adults living...

On  May 27, Reuters reported that Biohub, a philanthropic venture formed by Meta CEO Mark Zuckerberg and Dr. Priscilla Chan, developed a global model of protein biology to speed up drug discovery.

The anti-obesity drug (AOM) market in the United States is rapidly changing structurally.

The next frontier of human health may not be found in a hospital; it may be unlocked in a laboratory.

Longevity stocks are getting more attention as investors look for companies tied to longer lifespans, healthier aging, and rising demand for care. The theme is broader than drugmakers.